

**Title**

Different Human Papillomavirus Types Share Early Natural History Transitions in Immunocompetent Women

**Authors**

Sally N. Adebamowo<sup>1,2</sup>, Brian Befano<sup>2,3</sup>, Li C. Cheung<sup>2</sup>, Ana Cecilia Rodriguez<sup>2</sup>, Maria Demarco<sup>2</sup>, Greg Rydzak<sup>3</sup>, Xiaojian Chen<sup>2</sup>, Carolina Porras<sup>4</sup>, Rolando Herrero<sup>4,5</sup>, Jane J. Kim,<sup>6</sup> Philip E. Castle<sup>2,7</sup>, Nicolas Wentzensen<sup>2</sup>, Aimée R. Kreimer<sup>2</sup>, Mark Schiffman<sup>2</sup>, Nicole G. Campos<sup>2,6</sup>

**Table of contents**


Supplementary table 1. Weibull Hazard Ratio estimates for all HPV type clearance	2
Supplementary figure 1	3
Supplementary figure 2	4

**Supplemental Table 1.** Weibull Hazard Ratio estimates for all HPV type clearance

Model	Prevalent <30, all incident		
	HR	95% CI	P-trend
<b>Age in groups (years)</b>	18 - 29	1.00	
	30 - 44	0.93	0.89 - 0.98
	45-54	1.02	0.89 - 1.16
	55+	0.81	0.70 - 0.93
<b>Age in groups, subset to carcinogenic HPV types (years)</b>	18 - 29	1.00	
	30 - 44	0.96	0.90 - 1.03
	45-54	1.24	0.96 - 1.60
	55+	0.82	0.62 - 1.07
<b>Age in groups, subset to non-carcinogenic HPV types (years)</b>	18 - 29	1.00	
	30 - 44	0.89	0.83 - 0.95
	45-54	0.90	0.77 - 1.05
	55+	0.77	0.65 - 0.91
<b>HPV carcinogenic group</b>	Non-carcinogenic	1.00	
	Carcinogenic	0.88	0.85 - 0.91
	HPV16	1.00	
	HPV 18/45	1.09	1.00 - 1.19
<b>HPV group</b>	HPV 31/33/35/52/58	1.03	0.95 - 1.10
	HPV 39/51/56/59	1.20	1.12 - 1.29
	Non-carcinogenic	1.25	1.16 - 1.34
	18 - 29	1.00	
<b>Age (years) + carcinogenic group</b>	30 - 44	0.92	0.88 - 0.97
	45-54	0.98	0.86 - 1.12
	55+	0.78	0.68 - 0.90
	Carcinogenic (12 HR)	0.87	0.85 - 0.90

HR = Hazard Ratios; P-trend: likelihood ratio test.

**Supplemental Figure 1.** Time to clearance defined as first negative after last positive (non-parametric Turnbull estimator) of incident infections and prevalent infections in women under 30 years of age, by HPV risk class, in NHS, ALTS, and CVT. Follow-up was truncated at 4 years in the figure, by which point nearly all infections had cleared. HPV68 was excluded from the analysis, as the SPF10-LiPA assay used in the CVT cannot distinguish HPV68 and non-carcinogenic HPV73.



**Supplemental Figure 2** Time to clearance (non-parametric Turnbull estimator) of incident infections, including those with evidence of high-grade disease, and prevalent infections in women under 30 years of age, by HPV risk class, in NHS, ALTS, and CVT. Follow-up was truncated at 4 years in the figure, by which point nearly all infections had cleared. HPV68 was excluded from the analysis, as the SPF10-LiPA assay used in the CVT cannot distinguish HPV68 and non-carcinogenic HPV73.

